Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Background therapy Clear all
Completed Phase 2 Interventional

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

NCT01046422
View directory record Official record
Conditions
Diabetes Type 2
Interventions
BMS-770767, Placebo, Metformin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Lomita, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 4, 2026, 10:21 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

NCT01210001
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
24
States / cities
Muscle Shoals, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 4, 2026, 10:21 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT01714817
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BMS-188667, Mycophenolate mofetil, Prednisone, Placebo matching with BMS-188667
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Long Beach, California • San Leandro, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 4, 2026, 10:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

NCT03565068
View directory record Official record
Conditions
Schizophrenia
Interventions
MK-8189, Placebo, Background AAP Therapy
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 4, 2026, 10:21 AM EDT
Terminated Phase 2 Interventional Results available

A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis

NCT00424294
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-195,543, celecoxib, Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
39
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Upland, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 4, 2026, 10:21 AM EDT
Completed Phase 4 Interventional Results available

CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery

NCT00925756
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 4, 2026, 10:21 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils

NCT02501629
View directory record Official record
Conditions
Asthma, Elevated Blood Eosinophils, Oral Corticosteroid Dependence
Interventions
Reslizumab, Placebo, Non-Oral Corticosteroid (non-OCS) Asthma Medication, Oral Corticosteroid (OCS)
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Bakersfield, California • Long Beach, California • Clermont, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 4, 2026, 10:21 AM EDT
Terminated Phase 3 Interventional Results available

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

NCT04181762
View directory record Official record
Conditions
Lupus Nephritis
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 4, 2026, 10:21 AM EDT
Completed Early Phase 1 Interventional

PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

NCT03232164
View directory record Official record
Conditions
Prostate Cancer, Prostate Neoplasm
Interventions
18F-DCFPyL PET
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 4, 2026, 10:21 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577
View directory record Official record
Conditions
Prostate Cancer
Interventions
capivasertib, docetaxel, placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
37
States / cities
Yuma, Arizona • Beverly Hills, California • Cerritos, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 4, 2026, 10:21 AM EDT
Terminated Phase 2 Interventional Results available

CD40L Antagonism in Rheumatoid Arthritis (RA)

NCT05306353
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 4, 2026, 10:21 AM EDT
Active, not recruiting Phase 3 Interventional

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

NCT04136353
View directory record Official record
Conditions
Prostate Cancer
Interventions
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
Drug · Radiation
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
19
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Burlington, Massachusetts + 15 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 4, 2026, 10:21 AM EDT
Recruiting Phase 2 Interventional

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

NCT07157787
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
ALXN1920, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Loma Linda, California • San Diego, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 4, 2026, 10:21 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

NCT06559306
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 4, 2026, 10:21 AM EDT
Recruiting Phase 2 Interventional

A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

NCT07211685
View directory record Official record
Conditions
Alport Syndrome
Interventions
BAY 3401016, Placebo
Biological · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 4, 2026, 10:21 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT02105948
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
20
States / cities
Newport Beach, California • Rochester, Minnesota • Saint Charles, Missouri + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 4, 2026, 10:21 AM EDT
Terminated Phase 2 Interventional

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

NCT00913393
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
Interventions
FG-3019, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Buena Park, California • Lakewood, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Sep 4, 2026, 10:21 AM EDT
Completed Phase 4 Interventional Results available

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

NCT02451137
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 300 U/ml, Insulin glargine, 100 U/ml, Insulin detemir, Background Therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
407
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Guntersville, Alabama + 304 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 4, 2026, 10:21 AM EDT
Recruiting Not applicable Interventional

Enhanced Coordinated Specialty Care for Early Psychosis

NCT06071858
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder, Psychosis Nos/Other, Bipolar Disorder
Interventions
Care Coordination, Individual Peer Support, Digital Outreach, Cognitive Remediation, Multi-Family Group Therapy
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
Not listed
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Belmont, Massachusetts • Boston, Massachusetts • Cambridge, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 4, 2026, 10:21 AM EDT
Completed Not applicable Interventional

Improving Decision-Making for Low Health Literate Prostate CA Patients

NCT05800483
View directory record Official record
Conditions
Prostate Cancer
Interventions
Healium
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Male only
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Manhasset, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 4, 2026, 10:21 AM EDT
Recruiting Phase 3 Interventional

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Nipocalimab, Placebo, Standard of care treatment
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
36
States / cities
Beverly Hills, California • Fullerton, California • Hemet, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 4, 2026, 10:21 AM EDT
Terminated Phase 3 Interventional Results available

Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares

NCT01459796
View directory record Official record
Conditions
Gout
Interventions
Rilonacept, Placebo, Allopurinol
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
74
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 4, 2026, 10:21 AM EDT
Not listed Phase 3 Interventional

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

NCT02584478
View directory record Official record
Conditions
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
Interventions
AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Carboplatin
Drug
Lead sponsor
Advenchen Laboratories, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
8
States / cities
Long Beach, California • Miami, Florida • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 4, 2026, 10:21 AM EDT
Completed Phase 2 Interventional Results available

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

NCT00665847
View directory record Official record
Conditions
HIV-1
Interventions
Etravirine (TMC125), Optimized background regimen (OBR)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Mobile, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Sep 4, 2026, 10:21 AM EDT